ReviewFrontiers in neurology2026
RhoA/ROCK signaling as a potential convergent pathway in microbiota-gut-brain axis-related cognitive impairment.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment is increasingly recognized as a multifactorial neurological condition involving gut microbiota imbalance, impaired barrier function, neuroinflammatory activation, and disrupted synaptic plasticity. However, the molecular mechanisms that integrate these pathological events remain largely unclear. The RhoA/ROCK signaling pathway, a key regulator of actin cytoskeleton remodeling, intercellular junction dynamics, barrier permeability, inflammatory signaling, and neuronal structural plasticity, may represent a potential molecular interface connecting intestinal microbial disturbances with cognitive dysfunction. Accumulating evidence suggests that alterations in gut microbiota composition, microbiota-derived metabolites, and inflammation-related microbial signals can modulate RhoA/ROCK activity, thereby affecting intestinal barrier integrity and blood-brain barrier function, regulating systemic and neuroinflammatory responses, and influencing cognition-related processes, including synaptic remodeling, axonal guidance, and long-term potentiation. Nevertheless, the biological consequences of RhoA/ROCK activation are highly dependent on cellular and pathological contexts. Transient and spatially restricted activation may contribute to barrier restoration and synaptic maintenance, whereas persistent or excessive activation may promote barrier disruption and neuronal dysfunction. Although current evidence remains largely preclinical and heterogeneous, RhoA/ROCK signaling provides a potential mechanistic framework for understanding microbiota-gut-brain interactions in cognitive disorders. Further investigations are required to establish causal relationships and clarify its therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.